Doxorubicin Market
Doxorubicin Market Study by Lyophilized Doxorubicin Powder and Doxorubicin Solutions for Breast, Prostate, Ovarian, Lung, Bladder, & Stomach Cancer, and Leukemia from 2024 to 2034
Analysis of Doxorubicin Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Doxorubicin Market Outlook (2024 to 2034)
The global doxorubicin market is approximated at a value of US$ 940.5 million in 2024 and is forecasted to expand at a CAGR of 6.8% to reach US$ 1.81 billion by the end of 2034.
Introduction of nanaomaterials in cancer treatment is one of the notable doxorubicin market trends. The rising cases of cancer across the globe are primarily driving the demand for chemotherapy medications. Some of the widely used cancer medications are adriamycin, docetaxel, cyclophosphamide, cisplatin, and etoposide.
Cancer is one of the leading causes of death across the world and doxorubicin is used as the first line of treatment for it. Doxorubicin is used as chemotherapeutic drug since 1960s. Doxorubicin is witnessing a widespread used for the treatment of bone sarcomas and soft tissues, and cancer related to bladder, ovary, breast, and thyroid. Doxorubicin intercalate within DNA base pairs, leading to breakage of DNA Strands and further inhibition of DNA and RNA synthesis.
Anthracyclines, including doxorubicin (Adriamycin®) and daunorubicin (Daunomycin, Cerubidine®) were first used as antibacterial agents and were derived from the fungus Streptococcus peucetius.
The ongoing research activities and increasing initiatives from the respective governments in the North American region to increase awareness about cancer are expected to generate lucrative opportunities for doxorubicin vendors. This region is set to lead the global market in terms of revenue share throughout the forecast period.
- North America is estimated to account for 35.3% of the global doxorubicin market share in 2024.
- According to World Health Organization, cancer is the second-most cause of death in the European region.
- The Western Europe doxorubicin market size is anticipated to reach US$ 298.2 million by 2034.
The South Asia & Pacific and East Asia markets are also anticipated to offer lucrative revenue opportunities for doxorubicin suppliers owing to rising healthcare expenditures in these regions.
- Sales of doxorubicin drugs are foreseen to increase at a CAGR of 6.9% during the next 10 years in East Asia.
| Report Attribute | Detail |
|---|---|
| Doxorubicin Market Size (2024E) | US$ 940.5 Million |
| Forecasted Market Value (2034F) | US$ 1.81 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.8% CAGR |
| South Korea Market Value (2034F) | US$ 74.7 Million |
| Doxorubicin Solution Demand Growth (2024 to 2034) | 6.6% CAGR |
| Key Companies Profiled | Pfizer Inc.; Reddy’s Laboratories Ltd.; Changzhou Kinyond Pharmaceutical Co. Ltd.; Janssen-Cilag Pty Limited; Meiji Seika Pharma Co. Ltd.; Cipla Limited; Hikma Thymoorgan Pharmazie GmbH; Synbias Pharma AG; Novartis International AG; Teva Pharmaceutical Industries Ltd.; Accord Healthcare Ireland Ltd.; Cadila Healthcare Limited; MicroBiopharm Japan Co. Ltd.; TTY Biopharm Company Limited |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors are Influencing Sales of Doxorubicin across the World?
“Rising Prevalence and Awareness of Cancer Driving Need for Advanced Anti-Drugs”
- According to the World Health Organization, new cancer cases are expected to increase over 30 million by 2050 worldwide.
Rising cancer awareness is resulting in surge in number of diagnostic testing such as biomarkers, further contributing to the sales of anti-cancer drugs. The use of Doxil for metastatic breast cancer treatment is increasing. Several studies conclude that no one drug or therapy can be effective to cure cancer.
Thus, to overcome this situation doctors make use of cancer immunotherapy procedure. To remove cancer tumor majority of time surgical treatment procedure is applied. However, novel delivery approaches to cancer therapeutics are leading to the development of peptide-based drugs for cancer treatment.
“Introduction of Nanotechnology to Boost Efficiency of Cancer Therapeutics”
Integration of nanotechnology in cancer treatment is set to boost the effectiveness of doxorubicin drugs. This technology makes use of nanoparticles (NPs) from 1 to 100nm to detect cancer. Nano-medicine reaches the target location due to its small size and high surface volume ratio and effectively offers therapeutic benefits without any negative effects.
- Several clinical trials related to nano-tailored doxorubicin are under process. According to a recent report by ClinicalTrials.gov, the combination of liposomal Dox with microwave thermotherapy is expected to kill numerous tumor cells. It works according to high heat mechanism. The cancer cells are killed by heating them to several degrees above body temperature.
What Limitations Can Lower Adoption of Doxorubicin Drugs?
“Side Effects Associated with Use of Doxorubicin”
Doxorubicin or Dox can cause several side effects related to cardiotoxicity, gastrointestinal issues, and myelosuppression. These adverse effects can deter the use of doxorubicin for cancer treatment.
Healthcare experts and scientists should majorly focus on overcoming these issues by focusing on research activities. Also, the availability of other alternative treatment options such as immunotherapies and target therapies is expected to hamper the doxorubicin market growth in the coming decade.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Start-up Ecosystem
- Founded in 2021, Odyssey Therapeutics is a United States-based start-up that offers next generation immunomodulators and oncology medicines.
- Frame Therapeutics is a Dutch start-up that offers personalized cancer vaccines to patients. The company operates on their patented technology ‘FramePro’, which aids in the mitigation of cancer cells.
- ElyssaMed is a French start-up that offers antigenic peptides for the treatment of non-small-cell lung cancer (NSCLC) and neuroendocrine tumors. The solution is delivered through an intradermal injection and a cancer vaccine adjuvant.
Country-wise Analysis
Why are Doxorubicin Suppliers Thriving in the United States?
“Early Adoption of Technologically-advanced Cancer Treatment Procedures”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 289.2 Million |
| Growth Rate (2024 to 2034) | 8.1% CAGR |
| Projected Value (2034F) | US$ 632.5 Million |
The United States is the most lucrative market for doxorubicin on a global scale and this can be attributed to the increasing incidence of multiple cancers, the presence of advanced healthcare infrastructure, and rising awareness of cancer treatments.
Supportive government initiatives and rapid adoption of advanced treatments are also expected to provide lucrative opportunities for doxorubicin manufacturers. The United States Doxorubicin companies are focusing on development of new products to maximize their revenues and increase their market presence.
- In September 2020, Zydus Cadila, a leading name in the doxorubicin market, announced that it had received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome injection by the United States Food and Drug Administration.
What is the Demand Outlook for Doxorubicin in Japan?
“Ongoing Clinical Trials Will Offer Lucrative Opportunities for Doxorubicin Suppliers”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 49.9 Million |
| Growth Rate (2024 to 2034) | 2.3% CAGR |
| Projected Value (2034F) | US$ 62.5 Million |
- According to the Economist Report, Japan has a high number of cancer survivors compared to the total national population.
The most common cancer cases among Japanese patients are related to prostate, stomach, breast, and lungs. Japan is advancing in the field of cancer treatment. The ongoing research and development activities in Japan regarding the use of liposomal doxorubicin are set to increase the overall market growth.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which Type of Cancer Accounts for High Consumption of Doxorubicin?
“Rising Cases of Breast Cancer Driving Consumption of Doxorubicin Chemotherapy Medications”
| Attribute | Breast Cancer |
|---|---|
| Segment Value (2024E) | US$ 424.7 Million |
| Growth Rate (2024 to 2034) | 8% CAGR |
| Projected Value (2034F) | US$ 919 Million |
The world is witnessing a substantial increase in the incidence of breast cancer and this trend is anticipated to majorly influence doxorubicin sales across the world. Doxorubicin for breast cancer treatment is gaining popularity.
Adriamycin is used as a chemotherapy drug for breast cancer treatment. Adriamycin chemotherapy or doxorubicin chemotherapy damages the genes of cancer cell and effectively stops their reproduction.
Which is the Prime Distribution Channel for Doxorubicin?
“Availability of Advanced Medications Allow Hospital Pharmacies to Hold Leading Market Share”
| Attribute | Hospital Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 428.8 Million |
| Growth Rate (2024 to 2034) | 7.2% CAGR |
| Projected Value (2034F) | US$ 862.7 Million |
In healthcare settings pharmacies plays a vital role in providing all the latest medicine and therapeutics. Hospital pharmacies are set to hold a major market share throughout the forecast period. Cancer patients prefer hospitals for treatment due to the presence of advanced technologies and skilled experts.
The presence of pharmacies in the hospital settings makes convenient and quick access to medications for target patients. Furthermore, the pharmacies in the hospital are equipped with skilled staffs such as pharmacists and healthcare professionals who possess adequate knowledge of medicines and diseases.
Competitive Landscape
Key players in the doxorubicin market are investing in R&D activities to launch novel medications. The introduction of advanced cancer solutions increases their market position and revenue shares. They are also employing strategies such as mergers, acquisitions, and collaborations to increase their product offerings.
- In 2024 Johnson & Johnson completed the acquisition of Ambrx. This acquisition is expected to strengthen the Johnson & Johnson’s commitment to innovation in prostate cancer and lead to the development of next-generation antibody drugs and targeted oncologic therapeutics.
Key Segments of Doxorubicin Market Research
-
By Formulation :
- Lyophilized Doxorubicin Powder
- Doxorubicin Solutions
-
By Cancer Type :
- Breast Cancer
- Prostate Cancer
- Ovarian Cancer
- Lung Cancer
- Bladder Cancer
- Stomach Cancer
- Leukemia
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Formulation
- 6.2. Cancer Type
- 6.3. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Formulation
- 7.1. Lyophilized Powder
- 7.2. Solutions
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cancer Type
- 8.1. Breast Cancer
- 8.2. Prostate Cancer
- 8.3. Ovarian Cancer
- 8.4. Lung Cancer
- 8.5. Bladder Cancer
- 8.6. Stomach Cancer
- 8.7. Leukemia
- 8.8. Others
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. e-Commerce
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. Middle East & Africa
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Formulation, Cancer Type, Distribution Channel, and Region for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Pfizer Inc.
- 20.2. Reddy’s Laboratories Ltd.
- 20.3. Changzhou Kinyond Pharmaceutical Co. Ltd.
- 20.4. Janssen-Cilag Pty Limited
- 20.5. Meiji Seika Pharma Co. Ltd.
- 20.6. Cipla Limited
- 20.7. Hikma Thymoorgan Pharmazie GmbH
- 20.8. Synbias Pharma AG
- 20.9. Novartis International AG
- 20.10. Teva Pharmaceutical Industries Ltd.
- 20.11. Accord Healthcare Ireland Ltd.
- 20.12. Cadila Healthcare Limited
- 20.13. MicroBiopharm Japan Co. Ltd.
- 20.14. TTY Biopharm Company Limited
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Formulation, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Formulation, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Formulation, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Formulation, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Formulation, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Formulation, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the doxorubicin market in 2024?
The global doxorubicin market is calculated at US$ 940.5 million for 2024.
What is the sales outlook for doxorubicin for 2034?
The market for doxorubicin is projected to reach US$ 1.81 billion by 2034.
What is the estimated demand growth for the global market?
Demand for doxorubicin is foreseen to rise at a CAGR of 6.8% from 2024 to 2034.
Which type of doxorubicin is widely consumed?
Sales of lyophilized doxorubicin powder are forecasted to reach US$ 1.07 billion by 2034.
Which are the alternative drugs to doxorubicin?
Some of the drug alternatives include Verzenio (abemaciclib) and Ibrance (palbociclib).
Who are the well-known manufacturers of doxorubicin?
Pfizer Inc., Reddy’s Laboratories Ltd., Changzhou Kinyond Pharmaceutical Co. Ltd., and Janssen-Cilag Pty Limited are leading producers of doxorubicin.
Doxorubicin Market